Ypsomed newly supplies AstraZeneca with the Bydureon Pen

Burgdorf – Starting in the US from September 2014, the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide will be administered with the dual-chamber injection system Bydureon Pen, based on Ypsomed's LyoTwist® platform.

The Burgdorf diabetes specialist Ypsomed can announce another success in the Injection Systems business segment: The British company AstraZeneca, one of the largest biopharmaceutical companies in the world, will use an Ypsomed injection system for subcutaneous administration of its diabetes drug Bydureon.